ArticleChemical science2013
Glucose conjugation for the specific targeting and treatment of cancer.
Article in Chemical science, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed, 376 citations in OpenAlex.
- Nontoxic mRNA vehicles based on electrically neutral self-assembling peptides.Nature communications · 2026Article
- Glyco-Conjugation of Thiosemicarbazone Copper(II) Complexes Enhances Selectivity toward Cancer Cells Overexpressing GLUT1.ACS omega · 2026Article
- Development of Glycoconjugated MAGL Inhibitors with Glucose-Dependent Antiproliferative Activity.International journal of molecular sciences · 2026Article
- Advances in Chemotherapeutic Potential of Glycoconjugates against Cancer.Anti-cancer agents in medicinal chemistry · 2026Review
- Synthesis and Application of a Glucoconjugated Organometallic Rhenium Complex as an IR Imaging Probe for Glycolytic Cancer Cells.Molecules (Basel, Switzerland) · 2025Article
- Direct deoxygenative arylation of saccharides via phosphorus-assisted C-OH bond activation.Nature communications · 2025Article
- Preparation of ketonylScience advances · 2025Article
- Advancing engineering design strategies for targeted cancer nanomedicine.Nature reviews. Cancer · 2025Review
- Recent Advances in the Development of Metal-Glycoconjugates for Medicinal Applications.Molecules (Basel, Switzerland) · 2025Review
- GLUT3 enhances chemosensitivity in glioblastoma by transporting temozolomide and capecitabine.Cell death discovery · 2025Article
- In Vivo Visualization of Tumor Metabolic Activity with a Tetra Glucose-Conjugated Zinc-Phthalocyanine Photoacoustic Contrast.JACS Au · 2025Article
- Synthesis of New DltA Inhibitors and Their Application as Adjuvant Antibiotics to Re-Sensitize Methicillin-ResistantMolecules (Basel, Switzerland) · 2025Article
- Article
- Plant glycosides and glycosidases: classification, sources, and therapeutic insights in current medicine.Glycoconjugate journal · 2025Review
- Synthesis and Biological Activity of Glycosyl Thiazolyl Disulfides Based on Thiacarpine, an Analogue of the Cytotoxic Alkaloid Polycarpine from the AscidianMarine drugs · 2025Article
- Computational Modeling of Pharmaceuticals with an Emphasis on Crossing the Blood-Brain Barrier.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Effect of Glycoconjugation on Cytotoxicity and Selectivity of 8-Aminoquinoline Derivatives Compared to 8-Hydroxyquinoline.Molecules (Basel, Switzerland) · 2025Article
- Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach.Current drug targets · 2025Review
- Therapeutic applications of carbohydrate-based compounds: a sweet solution for medical advancement.Molecular diversity · 2024Review
- Oxime Linked Doxorubicin Glycoconjugates Improve the Specific Targeting of Glioblastoma in High-Grade Glioma Therapy.ACS medicinal chemistry letters · 2024Article
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Cancers of diverse origins exhibit marked glucose avidity and high rates of aerobic glycolysis. Increased understanding of this dysfunctional metabolism known as the Warburg effect has led to an interest in targeting it for cancer therapy. One promising strategy for such targeting is glycoconjugation, the linking of a drug to glucose or another sugar. This review summarizes the most salient examples of glycoconjugates, in which known cytotoxins or targeted anticancer therapeutics have been linked to glucose (or another glucose transporter substrate sugar) for improved cancer targeting and selectivity. Building on these examples, this review also provides a series of guidelines for the design and mechanistic evaluation of future glycoconjugates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.